A Phase 3 prospective, randomized, multicenter, open-label, controlled trial to assess the efficacy and safety of cellular immunotherapy with MDR-101 for induction of immune tolerance in recipients of HLA-Matched, living donor kidney transplants
Administered By
Awarded By
Contributors
- Ravindra, Kadiyala Venkata Principal Investigator
Start/End
- May 21, 2018 - May 4, 2021